Stratos Wealth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
VCM
N
Stratos Wealth Partners's REGN Position: Q1 2026 in Review
Stratos Wealth Partners increased its Regeneron Pharmaceuticals (REGN) stake by 6.8% in Q1 2026, buying an estimated $19.1K and bringing the position to 391 shares worth $302K. The position accounts for ﹤0.01% of the portfolio, ranked #1317.
Stratos Wealth Partners first reported a position in REGN in Q1 2017 and has held it in 22 quarters since. The position peaked at $819K in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Stratos Wealth Partners held 391 shares of Regeneron Pharmaceuticals worth $302K as of Q1 2026.
- Stratos Wealth Partners bought 25 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $19.1K.
- Regeneron Pharmaceuticals made up ﹤0.01% of Stratos Wealth Partners's portfolio in Q1 2026, its #1317 holding.
- Stratos Wealth Partners first reported a position in Regeneron Pharmaceuticals in Q1 2017 and has held it in 22 quarters since.
- Stratos Wealth Partners's Regeneron Pharmaceuticals position peaked at $819K in Q3 2024.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Stratos Wealth Partners's 13F filing for Q1 2026, filed 28 Apr 2026.